Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections

Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today ...
Nasdaq

Sonnet BioTherapeutics Unveils Innovative Immunotherapeutic Candidates

Sonnet BioTherapeutics Holdings (SONN) has issued an update. The Company has introduced two innovative immunotherapeutic drug candidates, SON-1411 and SON-1400, featuring a unique IL-18 variant. These ...
ascopubs.org

Combination treatment effect of an immunotherapeutic agent with microtubule inhibitors.

Relationship of angiotensin II receptor blocker (ARB) to the effectiveness of immune checkpoint blockade (ICB) in non-small-cell lung cancer (NSCLC) and inhibition of angiotensin II/AGTR1 signaling in ...
ascopubs.org

Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191. This is an ASCO ...
Nasdaq

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 ...